INTRODUCTION

47
Malaria and malnutrition are major causes of morbidity and mortality in children in sub-Saharan and an indicator of acute growth disturbances; and weight-for-age, which represents a synthesis 56 of linear growth and body proportion (5). In Africa, malnutrition is highly prevalent; 39%, 8%, 57 and 28% of children under 5 are stunted (height for age z-score<-2), wasted (weight-for-height z-58 score<-2), or underweight (weight-for-age z-score<-2), respectively (20) . have reported a lower risk, while others have reported no association (7, 9, 11, 12) . However, in
MATERIALS AND METHODS
92
Study Area and Population
93
This study was conducted in rural eastern Uganda in the district of Tororo. Malaria transmission 94 in this area is holoendemic, occurring perennially and with an entomological inoculation rate age 6 weeks to 12 months, (2) documented HIV status of mother and child, (3) agreement to 108 return to the study clinic for any febrile episode or other illness, (4) agreement to avoid 109 medications administered outside of the study protocol, (5) residence within a 30 km radius of 110 the study clinic, (6) currently breastfeeding if HIV-exposed, and (7) parent/guardian provision of 111 informed consent. All mother-child pairs received two long-lasting insecticide treated bednets 112 (ITNs), a safe water vessel, multivitamins, and condoms at the beginning of the study. All HIV-113 infected children received antiretroviral therapy (ART) consisting of nevirapine plus lamivudine plus zidovudine or stavudine, if eligible according to WHO criteria. All HIV-exposed children 115 and HIV-infected children received daily trimethoprim-sulfamethoxazole (TS) prophylaxis.
116
Following cessation of breastfeeding, HIV-exposed children who remained HIV-uninfected were 117 randomized to continue or discontinue TS through 24 months of age. Children who were HIV-118 exposed and subsequently seroconverted continued TS prophylaxis. 
Malaria diagnosis and treatment
121
Subjects were followed for all medical problems at a dedicated study clinic open 7 days a week. Hamburg, Germany), both precise to the nearest 100 grams. Recumbent length measurements 168 were taken using a steidiometer for children up to approximately 1 year of age. After that age, 169 standing height measurements were taken. All length and height measurements were precise to 170 the nearest 1 centimeter. Age was calculated using the date of birth of the child. 
RESULTS
224
Of the 351 participants enrolled in the study, 292 (83%) were diagnosed with at least one episode 225 of uncomplicated malaria and randomized to therapy. Of these, 145 were randomized to DP and 226 147 were randomized to AL, resulting in 981 and 1032 treatments for uncomplicated P.
227
falciparum malaria, respectively, that were included in this study (Figure 1 ).
229
Demographic and anthropomorphic baseline characteristics of all episodes of uncomplicated 230 falciparum malaria stratified by treatment are presented in Table 1 . At the time of treatment, 231 90% of study participants resided in a rural area, approximately one-third of all participants were 232 breastfeeding, 30 % were taking TS prophylaxis, 8.5% were HIV infected and 92% of these were 233 taking ARTs. Forty-three percent of the study participants had an HAZ z-score <-2 and 13% had 234 a WAZ z-score of <-2, consistent with rates reported across Uganda (15). In study participants not on TS prophylaxis treated with DP, the risk of recurrent parasitemia 254 after 42 days of follow-up increased as HAZ score decreased (log rank test p=0.03, Figure 2 ).
255
After controlling for age, place of residence, breastfeeding status, cumulative dose of 256 piperaquine received, and ART use, a decreasing HAZ score was independently associated with 257 a higher risk of recurrent parasitemia (Table 3) . However, statistical significance was reached 258 only when comparing HAZ scores <-1 with those > 0. There were no significant associations 259 between HAZ scores and the risk of recurrent parasitemia among patients treated with DP and 260 taking TS prophylaxis (Table 3) . Similarly, there were no significant associations between WAZ 261 scores and the risk of recurrent parasitemia among patients treated with DP, regardless of 262 whether or not the patient was taking TS prophylaxis (Table 3) .
264
In study participants not on TS prophylaxis treated with AL, the unadjusted risk of recurrent 265 parasitemia after 42 days of follow up increased as HAZ scores decreased (log rank test p=0.05, (Table 4) . As with DP, the WAZ 271 score was not associated with recurrent parasitemia in those not taking TS prophylaxis. In study participants taking TS prophylaxis, there was an association of WAZ scores and recurrent 273 parasitemia. However, this was only significant when comparing those with the lowest (<-2) and 274 highest WAZ score (<0 and ≥ -1) to a WAZ score ≥ 0 (Table 4) . parasitemia, a few studies have assessed the association between malnutrition and malaria risk.
298
In a cross-sectional study in Kenya of 1862 children under 36 months of age, stunted children 299 were more likely to have more parasitemia (OR=1.98) and clinical malaria (OR=2.65) than non-300 stunted children (11). Likewise, a prospective cohort study of 487 children under 5 in the 301 Gambia found that stunted children were at a higher risk of malaria (RR=1.35) than non-stunted 302 children (7). Contrary to our findings, a prospective cohort study of 136 children 4 months to 10 303 years of age in Papua New Guinea found the incidence rate of malaria (of any type, as well as P. found that stunting and being underweight were not associated with an increased risk of P.
308
falciparum malaria (9, 19). There may be several explanations for the conflicting findings. The 309 study conducted in Kenya was conducted in children of a similar age range to the children in the 310 Tororo study, while the studies conducted in Papua New Guinea and Burkina Faso were 311 conducted in older children. Moreover, the study in Kenya was conducted in an area of high 312 transmission (60 to 300 infective bites per person per year) whereas the studies which found 313 compromised nutritional status to be protective or to have no effect on malaria risk were 314 conducted in areas where malaria transmission occurred seasonally with lower transmission rates 315 than in Kenya as well as in the Tororo district in Uganda. Both the differences in age and 316 transmission intensity may lead to differences in acquired immunity and thus differences in 317 malaria risk. 
339
The few pharmacokinetic studies conducted in children have indicated that because of 340 differences in drug metabolism and elimination, children may be receiving suboptimal doses of antimalarial drugs (23, 27) . Additional analysis of data from a subset of this patient population, 342 including complete pharmacokinetic profiles, is currently underway.
344
Interestingly, the association of increased risk of recurrent parasitemia with decreasing HAZ was 345 evident only for children not taking TS prophylaxis. TS is an antifolate which has been 346 associated with reduced morbidity and mortality in HIV-infected children and adults. TS also 347 has antimalarial properties. Though TS has been used to treat P. falciparum malaria in the past, 
ACKNOWLEDGEMENTS
377
We are grateful to al the parents/guardians for kindly giving their consent and the study 378 participants for their cooperation. We thank the members of the Tororo study team. The 
